XAIR biotech catalysts & pipeline

BEYOND AIR INC · Data as of 2026-09-08

Upcoming catalysts

LungFit GO — FDA meeting

2026

We anticipate having discussions with the FDA in calendar 2026 to identify a path forward.

Source filing

second-generation LungFit PH system — Regulatory decision

2H CY2026

PMA supplement for second-generation LungFit PH system under FDA review; approval expected in 2H CY2026

Source filing

nitric oxide — Regulatory decision

Late 2026

We will continue to grow our business with LungFit PH as we prepare for the FDA clearance of our second-generation LungFit PH system, which we expect to receive before the end of calendar 2026, subject to regulatory review.

Source filing

nNOS inhibitors — Initial data

Late 2026

We expect this program to progress from preclinical to a phase 1 first-in-human clinical trial by the end of 2026.

Source filing

BA-102 — Initial data

in 2027

The Company is in preclinical development and expects to progress to a Phase 1 first-in-human clinical trial by the end of 2026, which could provide data in 2027.

Source filing

inhaled NO — Conference presentation

2026

We anticipate having discussions with the FDA in calendar 2026 to identify a path forward.

Source filing

Explore the free biotech catalyst calendar